New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine
Shots:
- New Brunswick joins British Columbia and Alberta in implementing a “switch” policy that changes coverage for specific biologic medicines
- Patients switching from reference biologics to biosimilar versions will continue receiving safe- effective treatment and will enable to save millions of dollars once implemented
- Sandoz is committed to supporting patients- their HCPs- and the New Brunswick Government with high quality biosimilar medicines and experienced- comprehensive patient support programs
Ref: Sandoz | Image: Sandoz
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com